For HER3, neither of the two included trials (the PICCOLO and CALGB 80203 trials) observed evidence for it as a prognostic biomarker but found tumor HER3 mRNA expression may be a useful predictive biomarker for anti-EGFR therapy in RAS wt patients (Table 6; Fig. 8a-c). Here, EGFR is linked to neoplasm.